The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•24 April 2026•

1 min read

Delaware Court Dismisses Tesaro's Breach Claim Against AnaptysBio

Key Facts

1The Delaware Chancery Court dismissed Tesaro's anticipatory breach of contract claim against AnaptysBio.

2The ruling agreed with AnaptysBio's position that it never repudiated the Collaboration and Exclusive License Agreement with Tesaro, a GSK subsidiary.

The Delaware Chancery Court has dismissed a legal claim filed by Tesaro, a subsidiary of GSK, against AnaptysBio regarding an alleged anticipatory breach of contract. The ruling validated AnaptysBio's position, confirming that the company never repudiated its Collaboration and Exclusive License Agreement with Tesaro. The dispute centered on the partnership for the drug Jemperli, with Tesaro claiming that AnaptysBio intended to breach their established terms. This judicial victory removes a significant potential liability for AnaptysBio and clarifies the status of a key revenue-generating collaboration. By dismissing the claims, the court has ensured the continuity of the licensing framework between the two biotech firms. This development is seen as a positive milestone for AnaptysBio's legal and operational stability.